This report examines the clinical utility of pharmacogenomic testing to inform the selection or dose of medications for individuals diagnosed with depression, mood disorders, psychosis, anxiety, attention-deficit/hyperactivity disorder, or substance use disorder. First, evidence is evaluated to determine whether pharmacogenomic test results change decisions regarding the drug or dose selected by physicians compared with usual care/no genetic testing. Then evidence is assessed as to whether those test-guided decisions result in clinically meaningful improvement in patient response to treatment, or reduction in adverse events as a result of treatment, compared with decisions based on usual care/no genetic testing.
If you have a Hayes login, click here to view the full report on the Knowledge Center.